Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.66 |
| ▸ | GSK3A | P49840 | 4/20 | 0.66 |
| ▸ | CDK1 | P06493 | 3/20 | 0.66 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.66 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175422 | 0.92 | GSK3B (0.64) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4399102 | 0.91 | GSK3B (0.67) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5099975 | 0.87 | GSK3B (0.63) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4671986 | 0.86 | GSK3B (0.58) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4401594 | 0.85 | GSK3B (0.75) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL7686134 | 0.85 | GSK3B (0.58) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5098978 | 0.84 | GSK3B (0.63) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4404418 | 0.84 | GSK3B (0.84) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4672216 | 0.84 | GSK3B (0.55) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5079017 | 0.84 | GSK3B (0.56) | GSK3BGSK3ACDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| US-6949547-B2 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030216574-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | NUSS JOHN M (US) | 2003-11-20 | — | — | US | disclosed |
| US-6608063-B2 | For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes | CHIRON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| EP-1237880-A2 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044206-A9 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-10-25 | — | — | US | disclosed |
| WO-2001044206-A1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 25/4885 |
| US-20030216574-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 25/4885 |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.